Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials

BACKGROUND: The usefulness of Gleason score (<8 or ≥8) at initial diagnosis as a predictive marker of response to abiraterone acetate (AA) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) was explored retrospectively. PATIENTS AND METHODS: Initial diagnosis...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Fizazi, K., Flaig, T. W., Stöckle, M., Scher, H. I., de Bono, J. S., Rathkopf, D. E., Ryan, C. J., Kheoh, T., Li, J., Todd, M. B., Griffin, T. W., Molina, A., Ohlmann, C. H.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279107/
https://ncbi.nlm.nih.gov/pubmed/26609008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv545
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items